Recordati
REC · Euronext Milan · Italy
Public Market Listing
RECEuronext Milan
Live quotes, historical charts, and market capitalization for Recordati are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(4 total)
4Total Assets
3Approved
0Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Icosapent Ethyl(Vascepa) | Approved | Omega-3 fatty acid (EPA)Small molecule | Atherosclerotic Cardiovascular DiseaseSevere Hypertriglyceridemia |
Lomitapide(Juxtapid) | Approved | MTPSmall molecule | Homozygous Familial Hypercholesterolemia |
Zilganersen(Zanvastro) | Approved | GFAP pre-mRNARNA / oligonucleotide | Alexander Disease |
| Preclinical / Unstaged | L-type calcium channels (Cav1.2)Small molecule | Hypertension |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
25 October 2026Topline resultIcosapent EthylEMT2 Phase 3 trial results: primary PFS endpoint not met, OS improved
US, FDA · Source ↗
US, FDA · FDA · Source ↗
Ionis Pharmaceuticals · Source ↗
Financial reports
No financial reports recorded.